Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Visionary Holdings Inc. GVHGF

Consumer Defensive — Education & Training Services

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
89.91%

Capital & Financial Ratios

Market Cap
0.70
Revenue
13.68
Net Income
(14.78)
Free Cash Flow
(42.16)
Net Debt
2.23
Current Ratio
0.07
Debt/Equity
0.49
P/E ratio
0.00
P/S ratio
0.06
P/B ratio
0.15
Past 5Y EPS Growth
40.75%
This Y EPS Growth
—
Next Y EPS Growth
—
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
—
Annual Dividend Rate
—
Annual Dividend Yield
—

Assets vs Liabilities

2022 2023 2024 2025
Cash 0.80 1.20 0.62 0.33
Receivables 0.43 0.28 0.10 1.53
Inventory — — — —
Other 0.61 20.86 — —
1.54 22.35 2.09 3.83
2022 2023 2024 2025
Payables 0.28 1.03 1.19 2.88
ST’ Debt 0.75 1.68 0.49 2.56
Other 10.65 0.38 — 0.29
13.28 80.46 69.68 58.31
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — — — —
5.04
’24 — — — —
9.38
’23 6.57 — 1.86 —
8.43
’22 2.01 — 3.24 —
5.25
’21 5.70 — — —
7.73
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’25 (2.97) — — —
(2.97)
’24 (4.10) — — —
(4.10)
’23 0.34 — (0.39) —
0.34
’22 6.36 — 1.78 —
6.36
’21 4.44 — — —
4.44
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’25 12.09 — — —
12.08
’24 8.51 — — —
8.51
’23 (62.37) — (0.39) —
(62.37)
’22 6.36 — 1.78 —
6.36
’21 4.44 — — —
4.44
in millions of $

EPS

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — — — —
(3.66)
’24 — — — —
0.32
’23 (0.02) — (0.07) —
(1.35)
’22 (0.01) — 0.01 —
0.00
’21 0.05 — — —
0.07

Target Price Range

High
—
—
Average
—
—
Low
—
—

Recommendation Rating

1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — — — 5.45 1.52 1.00 1.02 — — —
Low Price
— — — — — — 420.00 17.55 8.85 9.60 — — —
High Price
— — — — — ‡‡‡‡‡ 48 30 67 64 — — —
Employees
— — — — ‡‡‡ ‡‡‡‡‡ 0.11 0.28 0.14 0.08 — — —
Revenue/Emp
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 5.25 8.43 9.38 5.04 — — —
Revenue
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 49.76% 44.63% 27.07% 28.01% — — —
Gross Margin
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 0.26 (4.43) 1.54 (15.65) — — —
EBT
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 4.88% (52.58%) 16.43% (310.16%) — — —
EBT Margin
— — — — ‡‡‡ ‡‡‡‡‡ (0.06) (3.57) 0.97 (15.75) — — —
Net Income
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 0.49 1.39 2.44 2.12 — — —
Depreciation
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.25 3.27 2.90 1.16 — — —
Revenue/Sh
— — — — ‡‡‡‡ ‡‡‡‡ 0.00 (1.35) 0.32 (3.66) — — —
Earnings/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.73 0.13 (1.27) (0.68) — — —
Cash Flow/Sh
— — — — ‡‡‡ ‡‡‡ 0.00 (24.31) 3.91 3.47 — — —
Capex/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.73 (24.18) 2.64 2.79 — — —
Free CF/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 1.57 4.93 5.49 1.20 — — —
Book Value/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.33 2.58 3.23 4.33 — — —
Shares
— — — — ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 — — —
PE Ratio
— — — — ‡‡‡ ‡‡‡ 0.00 46.05 7.32 9.35 — — —
PS Ratio
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 4,081.63 49.53 5.64 24.63 — — —
PB Ratio
— — — — ‡‡‡ ‡‡‡ 0.00 46.17 7.33 9.54 — — —
EV/Sales
— — — — ‡‡‡ ‡‡‡ 0.00 78.06 (2.09) (3.09) — — —
EV/FCF
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 6.36 0.34 (4.10) (2.97) — — —
Op' Cash Flow
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (0.47) (62.70) 12.61 15.05 — — —
Capex
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 6.36 (62.37) 8.51 12.08 — — —
FCF
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (11.74) (58.11) (67.59) (54.48) — — —
Working Cap'
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 19.78 2.92 0.77 2.56 — — —
Total Debt
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 18.98 1.71 0.15 2.23 — — —
Net Debt
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 3.68 12.72 17.75 5.20 — — —
Sh' Equity
— — — — ‡‡‡ ‡‡‡‡‡ 0.04% (5.25%) 1.11% (20.92%) — — —
ROA
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.84% 1.87% (8.13%) (29.21%) — — —
ROIC
— — — — ‡‡‡ ‡‡‡‡‡ 0.28% (42.39%) 6.72% (138.11%) — — —
ROE
predictions in italic, sparklines do not include predictions

Visionary Holdings Inc. (GVHGF) Latest News

News by impact score

Fine-tune

10 Jun

4 GlobeNewswire, 1:42 PM
Visionary Holdings Inc. received a Nasdaq staff determination letter and plans to request a hearing to appeal. Nasdaq determination letter introduces delisting risk that threatens liquidity and investor confidence.

4 May

4 GlobeNewswire, 4:00 PM
Visionary Holdings Inc. (GV) received a Nasdaq delisting determination letter due to delinquent listing fees. Nasdaq delisting determination for unpaid fees threatens stock liquidity, investor confidence, and long-term market access.

10 Apr

3 GlobeNewswire, 9:30 AM
Visionary Holdings Inc. (GV) received a Nasdaq notification for failing to satisfy the minimum $1 bid price listing requirement over 30 consecutive business days. Nasdaq minimum bid price deficiency notification risks delisting and erodes investor confidence without immediate compliance.

7 Apr

4 GlobeNewswire, 9:31 AM
Visionary Holdings Inc. (GV) received a Nasdaq continued listing deficiency letter for failing to meet listing requirements. Nasdaq deficiency letter signals non-compliance risk, threatening delisting and eroding investor confidence.

31 Mar

4 GlobeNewswire, 10:01 AM
Visionary Holdings Inc. (GV) signed a cooperation agreement with a strategic investment partner for a proposed US$20 million investment in the Qingdao Anti-Aging Project. Proposed $20 million investment into anti-aging project marks a major strategic expansion likely to significantly boost GV's growth trajectory and investor sentiment.

26 Mar

4 GlobeNewswire, 9:30 AM
Visionary Holdings Inc. (NASDAQ: GV) enters strategic cooperation agreement to expand distribution capabilities for V-Series anti-aging products in China. Strategic agreement expands distribution of V-Series anti-aging products into China's vast market, positioning GV for substantial revenue growth and improved market performance.

9 Mar

4 GlobeNewswire, 8:30 AM
Visionary Holdings Inc. (GV) signs US$12 million exclusive agreement to double down on high-margin medical aesthetics business while initiating strategic exit from non-core operations. $12M exclusive deal in high-margin medical aesthetics plus exit from non-core businesses marks a major strategic shift to refocus on profitable core operations.

5 Mar

4 GlobeNewswire, 9:30 AM
Visionary Holdings Inc. (NASDAQ: GV) releases 2026–2027 growth outlook, with RAMU anti-aging product line targeting $30 million in potential annual sales. Growth outlook projecting $30 million annual sales from RAMU anti-aging line signals major revenue potential and strategic expansion.

2 Mar

4 GlobeNewswire, 9:30 AM
Visionary Holdings Inc. (GV) secures US$12 million exclusive agreement to double down on high-margin medical aesthetics while initiating strategic exit from non-core businesses. A $12M exclusive deal in high-margin medical aesthetics combined with exiting non-core operations marks a major strategic refocus poised to significantly improve financial trajectory and investor sentiment.

24 Feb

3 GlobeNewswire, 9:50 AM
Visionary Holdings Inc. (GV) announces continued progress on an approximately US$9 million sales contract. Ongoing progress on a $9 million sales contract signals moderate revenue potential without fundamentally altering company trajectory.

18 Feb

4 , 9:31 AM
Visionary Holdings Inc. (Nasdaq: GV) establishes three wholly owned subsidiaries in Qingdao, Wuxi, and Wuhu to advance commercial expansion in China. Establishing wholly owned subsidiaries in key Chinese cities enables major commercial expansion, significantly impacting future growth and market performance.

13 Feb

3 GlobeNewswire, 4:30 PM
Visionary Holdings Inc. has successfully secured $450,000 in debt financing to support its operations and growth initiatives. This funding is expected to enhance the company's financial position and facilitate future projects. The debt financing may moderately influence the company's financial performance and operational capabilities.

4 Feb

3 GlobeNewswireMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresCryptonewsMT Newswires, 2:44 PM
Visionary Holdings Inc. (GV) has resolved its filing deficiency with Nasdaq and confirmed its continued listing on the exchange. The company addressed the issues that led to the deficiency, ensuring compliance with Nasdaq's listing standards. This resolution allows GV to maintain its market presence and continue operations without interruption. Resolving the Nasdaq filing deficiency stabilizes the company's market position but does not fundamentally change its operational trajectory.

2 Feb

3 GlobeNewswire, 9:30 AM
Visionary Holdings Inc. has successfully regained compliance with Nasdaq's periodic filing requirements, addressing previous concerns regarding its financial reporting. This achievement allows the company to continue trading on the exchange without facing delisting risks, which is crucial for maintaining investor confidence and market presence. Regaining compliance with Nasdaq requirements positively influences investor sentiment and operational stability.

20 Jan

3 GlobeNewswire, 9:37 PM
Visionary Holdings Inc. has released its final fiscal year 2025 annual report and audited financial statements, with a Form 20-F filing pending. This correction addresses previous inaccuracies in the reporting process. The release of the annual report and audited financial statements may moderately influence investor sentiment and financial performance.

13 Jan

3 GlobeNewswire, 10:36 PM
Visionary Holdings Inc. has issued a correction regarding previous statements made about its financial performance and operational strategies. The company clarified discrepancies in its earnings report, emphasizing its commitment to transparency and accuracy in financial disclosures. This correction is expected to impact investor confidence and market perception of the company's reliability moving forward. The correction of financial statements may moderately influence investor sentiment and perceptions of the company's reliability.

12 Jan

4 GlobeNewswireGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comMarketBeatGuruFocus.com, 11:38 PM
Visionary Holdings Inc. (GV) has released its Annual Report for Fiscal Year 2025, detailing financial performance, strategic initiatives, and future outlook. The report highlights key metrics, including revenue growth and operational efficiencies, while outlining plans for product innovation and market expansion. Management emphasizes a commitment to enhancing shareholder value and navigating industry challenges effectively. The report outlines significant strategic initiatives and financial performance that could notably influence the company's future trajectory.

30 Dec

4 GlobeNewswireSimply Wall St.Simply Wall St.Medical Device NetworkTipRanksSimply Wall St.ZacksInternational Accounting Bulletin, 3:09 PM
Visionary Holdings Inc. (GV) has announced significant governance updates and a strategic shift towards high-end medical aesthetics. The company is also providing a timeline for its annual report filing, indicating a focus on enhancing its operational framework and market positioning in the evolving aesthetics sector. The strategic pivot to high-end medical aesthetics represents a major shift that could significantly alter the company's trajectory and investor sentiment.

4 GlobeNewswire, 9:30 AM
Visionary Holdings Inc. (Nasdaq: GV) has appointed a new CEO for its health technology business and established a new sales entity in Nanjing, China. This move aims to enhance commercial execution in the Chinese market, indicating a strategic focus on expanding operations and market presence in Asia. Establishing a new sales entity in China represents a significant strategic move that could enhance market penetration and revenue growth.

10 Nov

4 PR NewswirePharmaceutical Technologyetf.comPharmaceutical TechnologyGuruFocus.comPharmaceutical TechnologyPharmaceutical Technology, 9:30 AM
Visionary Holdings Inc. (Nasdaq: GV) has launched a new line of stem cell-based anti-aging products, marking a significant step in its expansion into Asia's premium regenerative medicine market. This initiative aims to capitalize on the growing demand for advanced anti-aging solutions in the region, positioning the company for increased market presence and potential revenue growth. The launch of a new product line in a high-demand market is likely to significantly impact future performance and investor sentiment.

4 Nov

4 PR Newswire, 9:30 AM
Visionary Holdings Inc. has successfully completed a leadership transition, establishing an elite governance team that aims to enhance operational efficiency and strategic direction. The new standardized structure is designed to empower high-quality development across the organization, positioning the company for future growth and innovation. The leadership transition and governance improvements are likely to significantly impact the company's strategic direction and market performance.

31 Oct

4 , 9:30 AM
Visionary Holdings Inc. successfully concluded its 2025 Annual General Meeting, completing a board renewal process that sets a new direction for compliant development within the company. This strategic move aims to enhance governance and align with regulatory standards, positioning Visionary Holdings for future growth and sustainability. The board renewal and new strategic direction are likely to significantly impact the company's governance and operational compliance, influencing investor sentiment and future performance.

22 Oct

4 PR Newswire, 9:30 AM
Visionary Holdings Inc. has announced the launch of a joint venture based in Toronto aimed at advancing the global commercialization of an innovative stem cell therapy for diabetes remission. This initiative targets a substantial market opportunity estimated at $150 billion, positioning the company to potentially capitalize on significant advancements in diabetes treatment. The joint venture represents a major strategic move that could significantly alter the company's trajectory and investor sentiment in the healthcare market.

17 Oct

4 PR Newswire, 9:30 AM
Visionary Holdings Inc. has completed a controlling stake acquisition in the Sikang Health Industry Joint Venture Platform, enhancing its global strategy in Traditional Chinese Medicine (TCM) health preservation. This move is expected to strengthen Visionary's position in the TCM market and expand its international footprint. Acquiring a controlling stake in a joint venture significantly enhances Visionary's strategic positioning and market presence in the TCM sector.

13 Oct

4 PR Newswire, 9:40 AM
Visionary Holdings Inc. (Nasdaq: GV) has secured a global license for a groundbreaking stem cell technology aimed at achieving diabetes remission and potentially a complete cure. This innovation targets a significant market valued at USD 150 billion, positioning GV to capitalize on a major healthcare advancement. The acquisition of a global license for a breakthrough technology in diabetes treatment is likely to significantly impact the company's future performance and market positioning.

24 Sep

4 PR Newswire, 9:30 AM
Visionary Holdings (Asia) Limited has entered into a strategic cooperation agreement with local accelerator Qianxin Bocheng (Jiangsu) to enhance the aesthetic treatment industry. This partnership aims to leverage local expertise and resources to advance innovative solutions in aesthetic treatments, potentially expanding Visionary Holdings' market presence and operational capabilities in the region. The strategic cooperation agreement is expected to significantly enhance Visionary Holdings' competitive positioning and market dynamics in the aesthetic treatment sector.

17 Sep

4 , 9:30 AM
Visionary Holdings Inc. (Nasdaq: GV) has announced a strategic alliance with Yike Regenerative Medicine aimed at tapping into the lucrative cellular rejuvenation and aesthetic treatment market, which is projected to be worth a trillion dollars. This partnership is expected to enhance GV's product offerings and market position in the rapidly growing sector of regenerative medicine. The alliance with Yike Regenerative Medicine is a significant strategic move that could greatly enhance Visionary Holdings' market position and financial performance in a high-value industry.

25 Aug

3 , 2:01 PM
Visionary Holdings Inc. has issued a warning regarding an unauthorized meeting of shareholders and a misleading website that falsely claims to represent the company. The board emphasizes that only official corporate communications should be considered reliable and reaffirms the importance of verifying information through legitimate channels. Unauthorized activities and misleading information can moderately affect investor confidence and the company's reputation.

22 Jul

4 CNW Group, 11:18 AM
Visionary Holdings Inc. announced a court ruling from the Ontario Superior Court of Justice regarding its Board of Directors and governance issues. The court ordered an investigation into allegations of misconduct and restrained Fan Zhou from management participation pending the investigation. Additionally, 3888 Investment Group Limited, controlled by Zhou's daughter, is also restrained from removing certain directors. The Board retains access to all Company records to ensure compliance with NASDAQ filing deadlines. The current Board, as of March 25, 2025, remains lawful until further notice. Visionary is committed to transparency and compliance with court orders. The court ruling and investigation could significantly impact the company's governance and investor sentiment.

5 Jun

4 , 9:00 AM
Visionary Holdings Inc. has established Visionary Health Technology Group Limited to enhance its presence in the HealthTech sector and the broader health industry. This strategic move aims to accelerate the company's growth and innovation in health-related technologies. The establishment of a dedicated health technology group is a significant strategic move that could greatly influence the company's future trajectory and market positioning.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us